Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 7.4%

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 4,230,000 shares, a growth of 7.4% from the July 15th total of 3,940,000 shares. Approximately 13.9% of the company’s shares are sold short. Based on an average daily volume of 421,200 shares, the days-to-cover ratio is currently 10.0 days.

Checkpoint Therapeutics Trading Up 5.0 %

Shares of NASDAQ CKPT traded up $0.11 during mid-day trading on Monday, reaching $2.32. The company had a trading volume of 407,705 shares, compared to its average volume of 469,417. Checkpoint Therapeutics has a 52-week low of $1.30 and a 52-week high of $3.62. The stock has a market cap of $82.79 million, a P/E ratio of -0.83 and a beta of 1.25. The firm has a 50 day simple moving average of $2.24 and a two-hundred day simple moving average of $1.99.

Insider Buying and Selling at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 13,038 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the transaction, the chief financial officer now directly owns 672,186 shares in the company, valued at $1,384,703.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the completion of the transaction, the chief executive officer now owns 1,977,170 shares in the company, valued at $4,053,198.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO William Garrett Gray sold 13,038 shares of the firm’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total value of $26,858.28. Following the completion of the sale, the chief financial officer now owns 672,186 shares in the company, valued at $1,384,703.16. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by company insiders.

Institutional Trading of Checkpoint Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its position in Checkpoint Therapeutics by 92.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock worth $26,000 after buying an additional 5,375 shares during the period. XTX Topco Ltd purchased a new stake in Checkpoint Therapeutics in the 2nd quarter valued at $34,000. Choreo LLC purchased a new stake in Checkpoint Therapeutics in the 4th quarter valued at $44,000. Magnus Financial Group LLC acquired a new stake in Checkpoint Therapeutics during the 4th quarter worth $55,000. Finally, Lindbrook Capital LLC purchased a new position in Checkpoint Therapeutics during the 1st quarter worth $62,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their target price on Checkpoint Therapeutics from $34.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, August 12th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.